Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR

##plugins.themes.academic_pro.article.sidebar##

Published Aug 17, 2016
Download
pdf
Vol. 94 No. 3 (2016): Issue Mar 2016

##plugins.themes.academic_pro.article.main##

Emna Abdelhamid
Sawsen Besbes
Aline Renneville
Olivier Nibourel
Nathalie Helevaut
Claude Preudhomme
Zohra Soua

Abstract

Abstract
Background: With the growing importance of minimal residual disease (MRD) monitoring and the recent discover of IDH mutations in acute myeloid leukemia (AML), the quantification of this molecular marker provides the possibility to monitor the disease progression and the therapy efficacy.
Objective: The aim of this study is to assess the MRD in AML for the first time with IDH1 and IDH2 gene mutations in 15 AML patients.
Methods: We have screened R132 IDH1, R140 IDH2 and R172 IDH2 mutations by PCR amplification and direct sequencing and we have quantified them for the first time by RQ-PCR using reverse primers modified by an LNA. A good sensitivity has been obtained. MRD rates obtained by LNA-RQ-PCR were used to draw kinetics of the disease evolution during the follow-up.
Results: IDH1/2 results were compared to NPM1 mutation and WT1 over expression and have showed coherent kinetic between MRD rates in 7/11 cases. For the rest, the direct sequencing and the high resolution melting (HRM) assay have confirmed the quantification results in diagnosis but not in residual samples.
Conclusion: Some optimization will be necessary to improve the mutated allele amplification. The LNA-RQ-PCR might be an easy and less cost method used in a small laboratory for myeloid leukemia MRD assessment using IDH1/2 mutations.

Keywords:

AML, MRD, LNA-RQ-PCR, IDH1/2 gene

##plugins.themes.academic_pro.article.details##

References

  1. Shen Y, Zhu Y, Fan X et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593-03.
  2. Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:978-82
  3. Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-43.
  4. Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2- hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339- 44.
  5. Marcucci G, Maharry K, Wu Y-Z et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-55.
  6. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86
  7. Yan H, Parsons W, Jin G et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 2009;360:765-73.
  8. Abbas S, Lugthart S, Kavelaars FG et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010;116:2122-6.
  9. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-21.
  10. Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013;98:648-57.
  11. Boissel N, Nibourel O, Renneville A et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010;28:3717-23.
  12. Kern W, Schoch C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56:283-09.
  13. Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantification in acute myeloid leukemia. Clin Lymphoma Myeloma 2009;9:1-9.
  14. Patel KP, Ravandi F, Ma D et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 2011;135:35-45.
  15. Rockova V, Abbas S, Wouters BJ et al. Risk stratification of intermediaterisk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011;118:1069-76.
  16. Chou W-C, Lei W-C, Ko B-S et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246-53.
  17. Veedu RN, Wengel J. Locked nucleic acid oligonucleotides toward clinical applications. Med Chem Nucleic Acids 2011;335-48.
  18. Giusto DA Di, King GC. Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities : implications for genotyping assays. Nucleic Acids Res 2004;32:1-8.
  19. Denys B, Housni H El, Nollet F, Verhasselt B, Philippe J. A Real-Time Polymerase Chain Reaction assay for rapid , sensitive , and specific quantification of the JAK2V617F mutation using a locked nucleic acidmodified oligonucleotide. J Mol Diagnostics 2010;12:512-9.
  20. Gabert J, Beillard E, van der Velden VHJ et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
  21. Abdelhamid E, Preudhomme C, Helevaut N et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 2012;36:316-23.
  22. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in nonsmall cell lung cancer. BMC Cancer 2006;6:295.
  23. Taylor CF. Mutation scanning using high-resolution melting. Biochem Soc Trans 2009;37:433-7.
  24. Erali M, Wittwer CT. High resolution melting analysis for gene scanning. Methods 2010;50:250-61.
  25. Scholl S, Theuer C, Scheble V et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008;80:208-15.
  26. Candoni A, Tiribelli M, Toffoletti E et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2008;82:61-8.
  27. Cilloni D, Gottardi E, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-21.
  28. Huang Q, Wang G, Huang J, Zhang B, Fu W. High sensitive mutation analysis on KRAS 2 gene using LNA / DNA chimeras as PCR amplification blockers of wild-type alleles. Mol Cell Probes 2010;24:376- 80.
  29. Zeng Y, Li D, Wang W et al. Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application. PLoS One 2014;9:1-10.